Morgan Stanley Remains Bullish on Eli Lilly (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly and Company (NYSE:LLY), raising the target price from $1,133 to $1,135.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

On July 9, Eli Lilly and Company (NYSE:LLY) announced that the US Food and Drug Administration (FDA) approved a label update with a new recommended titration dosing schedule for Kisunla, which is the company’s once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD).

The TRAILBLAZER-ALZ 6 study showed that “the modified titration schedule significantly lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) versus the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal and P-tau217 reduction”.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.